Search results

On one hand, I see accounts from reputable clinicians saying "there is no observable inflammation" (Edwards), and on the other hand, reputable clinicians saying "there is observable inflammation" (Klimas). So what conclusion is to be drawn here for the non-clinician on the sidelines? I think I...

Thanks for the input, and yes I agree. This is also why I ask people not to worry about it if they expect it to incur payback or have a good handle on their OI (captured in one of the questionnaires). We could probably have a whole thread about best ways to measure OI objectively (and/or...

I agree, which is why I have changed it to require the patient’s subjective score (not the attendee) and also to do versions of the analysis that don’t incorporate the score (or where I have run permutations with eg: bins of people who can’t attempt, people who can attempt but not complete). In...

Sorry i missed some things by accident including this (i realised this in the shower, lol, and I’m writing this from my phone). The correlation is a bit noisy, and depending on the assay 50-70ish controls. Yes we have remeasured some ppl longitudinally an that is for a forthcoming analysis +...

Going to give some quick responses as I try to finalise a paper today: Also important are substrate provision changes and elevated respiratory capacity (also mTORC1 activity in what may be a subset) but I didn't have the time for this nuance in the presentation. re: C5 deficiency - my...

The absolute OCR are higher in Fluge but this varies with the seahorse model used so I wouldn’t worry about it too much. I’ve worked with multiple models and the absolute values definitely do vary even with the same samples in side by side comparison and cell numbers adjusted to well area. As a...

Hah, foreshadowing. I have questions for the authors @chillier (does audrey also have an account?). The tone might appear direct but I'm just rapid-firing questions while reading the paper during a brief window of time, so please don't read into it. (I'm not mean, please don't take the...

We are looking at the epigenome of the cell lines at the moment. Could be something in the areas not wiped by the EBV I think that the bulk of the evidence for this shift is pointing to it being observable predominantly in immune cells. I am privy to under-wraps information that supports this...

the EVs could be coming from any tissue

Jess is right here, we love to interpret and speculate but with omics data it's really a discovery process for downstream testing. I wouldn't get too hung up on specifics. Speculation is useful but we can only reasonably do so much of it with this type of data. Hopefully the changing landscape...

It is likely that Australian studies I design this/next year will try to answer questions raised by Jonathan's paper

per protein imputation frequency is in the supplementary files

For sure. Yep and I think the evidence that comes to mind supports this too, at least in tissues that have been looked at directly Yep, possibly a story of signalling upstream of the mitochondria. May also not be, but we are testing this atm. (also could be interplay between both, and also...

I think the autophagy angle is coming from their microglia ROS proposal in the 2022 ATG13 paper, but that serum treatment experiment was tested using what I recall to be only a handful of serum samples and also yes it's just one of many possibilities. That was a nice line of methodical enquiry...

I wouldn't say so, to be honest Study 1) AMPK activity not found to be increased after exercise Study 2) AMPK is activatable pharmacologically (one would expect this in the absence of concrete evidence of a defect) Study 3) Differences in phenotypes when provisioned with different substrates...

Most journals mandate this these days (for omics data) so we will see pretty much everybody doing it in future

Also, relevant for me to update that we have overhauled (and continue to improve) our clinical phenotyping so that we can extract more from the newer studies, and the studies we are currently collecting new data for or recruiting for will look at some of these aspects

An intro thread is a good idea, I will need to find time to set it up, but a good idea re: commercial partners. A couple of companies reached out wanting to validate some of the more accessible measurements we found that could be discriminatory. Since initiating this, it went up the chain...

I haven't read the paper properly yet but if this is tricky to figure out it's important that it gets addressed. I am very interested in testing the ideas in the paper and the more info available the better the design will be

good to know that I am not the only one that can't think about anything else